DESIGNATES PMN350 ITS SECOND LEAD PRODUCT FOR DEVELOPMENT IN ALZHEIMER'S DISEASE
Promis Neurosciences Inc. (PMN.T) has designated PMN350 -- a monoclonal antibody (mAb) targeting toxic prion-like forms of amyloid-beta oligomers (AsO) -- as the company's second lead product for Alzheimer's disease (AD).
"We previously demonstrated that PMN310, our first lead product for development in Alzheimer's disease, presents the optimal target profile of selectively binding prion-like forms of AsO, inhibiting both their propagation and neurotoxicity," stated Dr. Neil Cashman, Promis chief scientific officer. "We have now achieved a significant development milestone by demonstrating that PMN350, our second AD lead product directed against a different target on toxic AbO, also displays the optimal target product profile in both in vitro and in vivo tests."
The neuroprotective effect of PMN350 was investigated at SynAging SAS, a leading contract research organization (CRO) specializing in neurodegenerative diseases. Injection of prion-like forms of AsO (also called toxic soluble oligomers) into the brains of mice causes a neurological deficit that can be assessed in a memory-behaviour test called novel object recognition. Normal mice exposed to an object remember the familiar object when re-exposed to it and spend more time exploring a newly introduced object. In contrast, AsO-injected mice lose the ability to discriminate between known and novel objects and spend equivalent amounts of time exploring both. Results obtained in this assay showed that administration of PMN350 to mice completely prevented the cognitive impairment caused by toxic oligomers. Furthermore, the observed cognitive benefit of PMN350 was correlated with a statistically significant improvement of two synaptic biomarkers (SNAP25, PSD95) and a biomarker of inflammation (TNFa) measured in hippocampal brain homogenates.
"We are pleased that our propriety discovery engine has produced a second lead product with the potential to treat Alzheimer's," commented Dr. Elliot Goldstein, Promis president and chief executive officer. "With two lead development products, PMN310 and PMN350, each selectively addressing a different target (epitope) on toxic prion-like forms of amyloid-beta oligomers, we look forward to initial evaluation of their relative prevalence in cerebrospinal fluid samples from Alzheimer's patients, thereby paving the way for a precision medicine approach to this devastating disease."
About Promis Neurosciences Inc.
The mission of Promis Neurosciences is to discover and develop precision medicine therapeutics for effective treatment of neurodegenerative diseases -- in particular, Alzheimer's disease and amyotrophic lateral sclerosis.